EIR Biopharma, a preclinical biotechnology company focused on developing therapies for eye diseases, has filed with the U.S. Securities and Exchange Commission (SEC) to raise up to $17 million in an initial public offering.

According to its filing, the company plans to offer 3.8 million shares at a proposed price range of $4 to $5 per share, which would value the offering at approximately $17 million at the midpoint. EIR Biopharma intends to list its shares on the NYSE American, though it has not yet selected a ticker symbol.

Founded in 2022 and headquartered in San Francisco, EIR Biopharma is an early-stage biopharmaceutical company that focuses on in-licensing preclinical drug candidates from academic institutions and advancing them toward clinical development.

EIR’s lead product candidate, EIR-0205, is a small-molecule therapy in development for dry age-related macular degeneration (AMD). The compound is designed to extract lipofuscin—a toxic metabolic byproduct that accumulates in the retinal pigment epithelium and contributes to retinal degeneration. 

The company’s second program, EIR-1003, is a peptidomimetic candidate engineered to mimic ephrin ligands, proteins involved in cellular signaling. The therapy is intended to promote retinal nerve regeneration in patients with optic nerve injury, a condition that can result in permanent vision impairment.

EIR Biopharma is currently conducting IND-enabling studies for both EIR-0205 and EIR-1003. The company plans to submit investigational new drug (IND) applications and initiate first-in-human clinical trials beginning in 2027, according to its SEC filing. Proceeds from the IPO are expected to support continued preclinical development, regulatory preparations, and general corporate purposes as the company advances its pipeline toward the clinic.